Medtronic (NYSE:MDT) Issues Q2 2027 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its second quarter 2027 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.320-1.340 for the period, compared to the consensus EPS estimate of 1.350. The company issued revenue guidance of -. Medtronic also updated its FY 2027 guidance to 5.940-6.000 EPS.

Medtronic Stock Up 0.1%

Shares of MDT opened at $92.10 on Thursday. Medtronic has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The stock has a 50 day simple moving average of $86.27 and a two-hundred day simple moving average of $85.35. The firm has a market cap of $117.89 billion, a P/E ratio of 22.69, a P/E/G ratio of 2.15 and a beta of 0.56.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The firm had revenue of $9.76 billion for the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a return on equity of 14.89% and a net margin of 13.93%.The company’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same period last year, the firm earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, analysts forecast that Medtronic will post 5.96 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio is presently 70.94%.

Analysts Set New Price Targets

MDT has been the topic of a number of research reports. Bank of America boosted their target price on shares of Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday. UBS Group raised shares of Medtronic from a “neutral” rating to a “buy” rating and raised their target price for the company from $85.00 to $100.00 in a research note on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft dropped their price target on Medtronic from $100.00 to $78.00 and set a “hold” rating on the stock in a research report on Thursday, June 4th. Needham & Company LLC increased their target price on Medtronic from $101.00 to $114.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Finally, Evercore set a $105.00 price target on Medtronic in a research report on Monday, July 6th. Nineteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $102.96.

Insider Activity

In other news, EVP Harry Skip Kiil sold 4,189 shares of the company’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares in the company, valued at $2,994,539.88. This represents a 10.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.27% of the stock is currently owned by insiders.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Beat-and-raise results: Medtronic reported fiscal Q1 FY2027 adjusted EPS of $1.45, ahead of the $1.39 consensus, while revenue increased 13.7% year over year to $9.76 billion, exceeding estimates. Growth was broad-based, led by cardiovascular sales, with additional contributions from neuroscience, medical surgery and diabetes. Medtronic Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Higher fiscal-year outlook: Management raised fiscal 2027 organic revenue-growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00. Analysts viewed the update as evidence that growth is accelerating across the portfolio, although the outlook benefited from an extra fiscal week in the quarter. Medtronic Begins Fiscal 2027 With a Beat-and-Raise
• Positive Sentiment: Robotics and heart-tech expansion: Medtronic committed approximately $700 million to a strategic partnership with Cornerstone Robotics, gaining rights to distribute its Sentire surgical system in select markets outside the United States. It also plans to invest up to $80 million in Pi-Cardia to support complex transcatheter aortic-valve replacement procedures. These deals broaden Medtronic’s growth platforms alongside its Hugo robotic system. Medtronic Announces Strategic Partnership with Cornerstone Robotics
• Positive Sentiment: Supportive analyst views and trading activity: RBC reaffirmed an Outperform rating with a $118 target, while BTIG raised its target to $100 and kept a Buy rating. Unusually heavy call-option activity also indicates increased speculative interest following the earnings report. Medtronic Analysts Raise Their Forecasts
• Neutral Sentiment: Stifel raised its price target to $95 but retained a Hold rating, and Baird lifted its target to $100 while maintaining Neutral, signaling that valuation and execution remain considerations despite the improved outlook. Medtronic Shares Gap Up on Better-Than-Expected Earnings

Institutional Investors Weigh In On Medtronic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC lifted its stake in shares of Medtronic by 0.3% during the 4th quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock valued at $3,120,000 after buying an additional 101 shares in the last quarter. Rossby Financial LCC boosted its stake in shares of Medtronic by 5.1% in the fourth quarter. Rossby Financial LCC now owns 2,193 shares of the medical technology company’s stock worth $211,000 after acquiring an additional 107 shares during the period. Wealthspire Retirement LLC raised its stake in Medtronic by 5.0% during the 4th quarter. Wealthspire Retirement LLC now owns 2,410 shares of the medical technology company’s stock valued at $232,000 after purchasing an additional 114 shares during the period. Mitchell Mcleod Pugh & Williams Inc. lifted its holdings in Medtronic by 2.0% in the 4th quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 6,043 shares of the medical technology company’s stock worth $622,000 after purchasing an additional 117 shares in the last quarter. Finally, Florida Financial Advisors LLC grew its holdings in Medtronic by 4.8% during the 2nd quarter. Florida Financial Advisors LLC now owns 2,683 shares of the medical technology company’s stock valued at $234,000 after buying an additional 122 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).